Ending the guesswork in cancer care

We believe cancer care should be as precise and personal as possible. Solid IO’s tumor-on-chip platform is transforming oncology, delivering real-time, patient-specific insights that empower clinicians to make life-changing treatment decisions. With Solid IO, the next era of precision oncology begins here.

Our solution

OUR MISSION

Bridging science

and care

At Solid IO, we combine deep scientific expertise with real-world clinical impact. Our team is pioneering patient-specific organ-on-chip technology to transform cancer care. By bridging the gap between research and treatment, we turn biological complexity into clear, actionable insights. The result? Smarter decisions, more precise therapies, and a future where personalized medicine isn’t just possible — it’s standard.

Our platform

Replicating the tumor environment

Solid IO replicates a patient’s tumor microenvironment, generating real-time insights into how cancers respond to immuno-oncology treatments. By combining our technology with bioengineering and AI, we enable precise, informed treatment decisions - before and during therapy.

Tailored precision

Captures each patient’s unique biology, delivering high-accuracy predictions of treatment responses.

Scalable simplicity

Works across multiple cancer types and immuno-oncology therapies, making precision diagnostics accessible to clinicians and researchers worldwide.

Collaborative power

We connect researchers, clinicians, and pharmaceutical innovators to drive immunotherapy and precision oncology breakthroughs.

More precise cancer treatment

Deliver targeted, data-driven treatments from day one, reducing trial and error.

Faster drug development

Shorten preclinical and clinical trial timelines, accelerate approvals and patient access.

BENEFITS

Precision with

impact

Better patient outcomes

Tailor treatments to reduce side effects and improve quality of life.

Expanding global access

Make advanced cancer diagnostics scalable and accessible worldwide.

Our partners

PARTNER WITH US

To the leaders and pioneers in cancer care

You drive innovation in cancer care. We are here to support your work - helping you accelerate therapeutic breakthroughs, personalized care, and advance cancer diagnostics. Let’s connect and explore how we can expand IO access together.

Let's connect

LEADERSHIP TEAM

Meet the pioneers

We are a growing team of dedicated, multidisciplinary experts in oncology, bioengineering, AI, and commercialization, all united by the mission to end guesswork in cancer care.

Noora Hujala

CEO, Founder
MSc (Health), BSc (Pharma), EMBA

Noora combines broad experience in health and pharma, commercial insight, and business acumen with a relentless drive to transform healthcare, ensuring scientific innovation translates into real impact where it matters most—patients' lives. "In healthcare, medicine advances, technology evolves - but at the heart of it all is a human being, hoping for a good life."

Heidi Haikala

CSO, Founder
PhD (Translational Cancer Biology), Assistant Professor, Principal Investigator, MBA -25

Heidi is a cancer scientist with deep expertise in translational oncology, immunotherapy, and functional drug testing. Following her postdoctoral training at Dana-Farber Cancer Institute & Harvard Medical School, she established her own research group at the University of Helsinki and Tampere University, focusing on translating preclinical discoveries into clinical applications. As the CSO of Solid IO, she is dedicated to advance precision drug testing and improve treatment decision-making for cancer patients.

CAREERS

Join Us!

If you would like to be part of our growing team, connect with us to explore opportunities at Solid IO.

Contact us
BLOG

Latest posts

View more posts

FAQs

Solid IO’s organ-on-chip platform replicates the patient’s tumor microenvironment, including immune interactions, to provide real-time insights into therapy responses. This technology enables more precise treatment selection, advances immunotherapy research, and supports early-stage clinical trials for new drug development.

By offering patient-specific, biology-driven insights, our platform helps oncologists and researchers make more informed decisions about treatment selection. This reduces trial-and-error, improves patient outcomes, and minimizes unnecessary side effects. Additionally, it accelerates immuno-oncology drug development by providing early biomarker validation and patient stratification insights within.

Our platform supports pharmaceutical companies, biotech firms, and cancer clinics involved in immunotherapy and precision oncology research. It helps optimize drug development pipelines, refine patient selection for clinical trials, and improve preclinical modeling for targeted therapies.

Currently, our platform is for research use only (RUO). We are actively collaborating with partners in pharma, biotech, and clinical research to refine and validate the technology. We welcome new partners to join us in shaping the future of precision oncology.

Our technology supports early patient stratification, biomarker validation, and real-time monitoring of treatment responses. These capabilities help shorten clinical trial timelines, reduce development costs, and improve the likelihood of success in bringing new immuno-oncology therapies to market.

Unlike traditional diagnostic models, our platform integrates patient-specific tumor environments with immune response modeling. This enables real-time insights into immunotherapies and combination treatments, providing a more accurate and scalable approach to personalized cancer care.

We collaborate with leading pharmaceutical companies, biotech firms, and cancer research centers to advance immuno-oncology treatments and precision oncology. Our partnerships focus on optimizing trial design, refining treatment selection, and accelerating access to next-generation therapies.

We are focused on expanding our global footprint, strengthening collaborations in the U.S. and European markets, and advancing our technology toward clinical applications. Our goal is to drive the adoption of organ-on-chip innovation in real-world oncology settings.

We are actively seeking partners - researchers, clinicians, and investors — who share our mission to end guesswork in cancer care. Get in touch through our Contact Us page to explore collaboration opportunities.

Shape the future of cancer care

Real progress happens through collaboration. We invite bold, forward-thinking partners- researchers, clinicians, and investors - to join us in making precision medicine truly impactful, and the new stanard in cancer care.

Contact us